HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: A viral-suppression-independent mechanism

Blood

Volumn 96, Issue 1, 2000, Pages 250-258

  Lu, Wei ^a,b   Andrieu, Jean Marie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Hopital Laennec   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; APOPTOSIS; ARTICLE; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS PATHOGENESIS;

EID: 0034235402     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.1.250.013k28_250_258     Document Type: Article

References (34)

1. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011-1017.
2. Hammer SM, Squires KE, Hugher MD, et al. A controlled trial of two nucleoside analogues plus indinavir in patients with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997; 337:725-733.
3. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997; 276:960-964.
4. Li TS, Tubiana R, Katlama C, Calvez V, Mohand HA, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet. 1998;351:1682-1686.
5. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
6. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995,373:117-122.
7. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
8. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med. 1998;4:208-214.
9. + T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med. 1998;4:794-801.
10. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART): Swiss HIV Cohort Study. Lancet. 1998;351:723-724.
11. + cell counts despite persistently detectable HIV load. N Engl J Med. 1998;338:1074-1075.
12. Cohen J. AIDS therapy: failure isn't what it used to be . . .but neither is success. Science. 1998; 279:1133-1134.
13. Aziz N, Nishanian P, Taylor JM, et al. Stable plasma levels of cytokines and soluble activation markers in patients with immunodeficiency virus infection. J Infect Dis. 1999;179:843-848.
14. Fahey JL, Tayler JM, Detels R, el al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322;166-172.
15. 2-microglobulin and prediction of progression to AIDS in HIV infection. Lancet. 1992;339: 1436-1440.
16. Andrieu JM, Lu W. Viro-immunopathogenesis of HIV disease: implications for therapy. Immunol Today. 1995;16:5-7.
17. + T lymphocytes from activation-induced apoptosis triggered by HIV-1 : implication for pathogenesis and therapy. AIDS. 1995;9:35-42.
18. Andrieu JM, Lu W, Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis. 1995;171:523-530.
19. Young B, Johnson S, Bahktiari M, et al. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis. 1998; 178:1497-1501.
20. Lorenzi PL, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS. 1997;11:F95-F99.
21. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlations of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996;70:8270-8276.
22. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutation in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760-766.
23. + T helper cell depletion occurs. J Clin Invest. 1988;82:1908-1914.
24. + cell number and clinical staging. J Clin Invest. 1989; 84:1892-1899.
25. Van Noesel CJ, Gruter RA, Terpstra FA, Schelledens PT, Van Lier RA, Miedema F. Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus infected men. J Clin Invest 1990; 86:293-299.
26. Bass HZ, Fahey JL, Nishanian P, et al. Relation of impaired lymphocyte proliferative function to other major human immunodeficiency virus type 1-induced immunological changes. Clin Diagn Lab Immunol. 1997;4:64-69.
27. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-358.
28. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993;362:359-362.
29. Finkel TH, Tudor-Williams G, Banda NK, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV and SIV-infected lymph nodes. Nat Med. 1995;1: 129-134.
30. Lu W, Andrieu JM. Apoptosis and HIV disease. Nat Med. 1995;1:386-387.
31. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999;353:863-868.
32. + T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood. 1999;94:1021-1027.
33. Bohler T, Walcher J, Golzl-Wening G, et al. Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. AIDS. 1999;13:779-789.
34. + T cell count, and HIV plasma viral copy number. AIDS Res Hum Retroviruses. 1999;15:1509-1518.